Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1984-2-14
|
pubmed:abstractText |
This study was performed to elucidate mechanisms responsible for the contraction of isolated canine cerebral arteries induced by uridine 5'-triphosphate (UTP) and to ascertain whether UTP given intracisternally causes cerebral arterial constriction. The latter was proven arteriographically to be the case. In vitro, UTP (10(-4)M) and UDP were similar in potency, produced sustained contractions, and were more effective than other pyrimidine nucleotides or uridine. Unlike serotonin (5-HT), UTP was not antagonized by cinanserin and failed to cause constriction of mesenteric arteries. Adenosine similarly antagonized 5-HT and UTP. The Ca2+ antagonist nimodipine abolished contractions caused by high K+ but only incompletely antagonized 5-HT or UTP. On the other hand, procedures that hyperpolarize the cell membrane (low K+ followed by K+) abolished tonic contractions induced by UTP. Hyperpolarization prior to UTP (with or without nimodipine) did not, however, prevent the occurrence of a phasic contraction. Papaverine or lanthanum antagonized this phasic response. It was concluded that UTP selectively affects cerebral arteries, may initiate contraction by releasing membrane bound Ca2+, depolarizes the cell membrane to open receptor operated and potential sensitive calcium channels, but does not inhibit the electrogenic Na-pump nor specifically antagonize the vasodilator adenosine.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidine Nucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Uracil Nucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Uridine Triphosphate
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0039-2499
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
347-55
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:6658902-Animals,
pubmed-meshheading:6658902-Calcium Channel Blockers,
pubmed-meshheading:6658902-Cerebral Arterial Diseases,
pubmed-meshheading:6658902-Cerebral Arteries,
pubmed-meshheading:6658902-Cisterna Magna,
pubmed-meshheading:6658902-Dogs,
pubmed-meshheading:6658902-Dose-Response Relationship, Drug,
pubmed-meshheading:6658902-Female,
pubmed-meshheading:6658902-Injections,
pubmed-meshheading:6658902-Male,
pubmed-meshheading:6658902-Pyrimidine Nucleotides,
pubmed-meshheading:6658902-Serotonin,
pubmed-meshheading:6658902-Spasm,
pubmed-meshheading:6658902-Time Factors,
pubmed-meshheading:6658902-Uracil Nucleotides,
pubmed-meshheading:6658902-Uridine Triphosphate,
pubmed-meshheading:6658902-Vasoconstriction
|
pubmed:articleTitle |
Mechanisms of the contractile effect induced by uridine 5-triphosphate in canine cerebral arteries.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|